Sadakatsu Ikeda
Tokyo Medical and Dental University
H-index: 27
Asia-Japan
Top articles of Sadakatsu Ikeda
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck …
The Lancet Oncology
2024/3/29
Effective Treatment of Lung Adenocarcinoma With a Novel SLC44A1-BRAF Fusion Using Pembrolizumab Followed by Trametinib: A Case Report
Cureus
2024/2/23
Sadakatsu Ikeda
H-Index: 19
426P Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Annals of Oncology
2023/11/1
O1-2 Prospective study of comprehensive genomic profiling for chemotherapy-naive cancer patients (FIRST-Dx study)
Annals of Oncology
2023/11/1
Tomohiro Kondo
H-Index: 5
Sadakatsu Ikeda
H-Index: 19
Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches
2023/9/14
Sadakatsu Ikeda
H-Index: 19
First-line genomic profiling in previously untreated advanced solid tumors for identification of targeted therapy opportunities
JAMA Network Open
2023/7/3
Tomohiro Kondo
H-Index: 5
Sadakatsu Ikeda
H-Index: 19
Comprehensive genomic profiling before the first-line setting versus after the completion of standard of care in patients with previously untreated advanced solid tumors: The …
2023/6/1
Sadakatsu Ikeda
H-Index: 19
Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in Japan
Cancer Science
2023/4
Yusuke Sato
H-Index: 27
Sadakatsu Ikeda
H-Index: 19
A Primary Kidney Giant Cell Tumor of Soft Tissue Caused Peritoneal Dissemination, Considered to Be Malignant Transformation: A Case Report
Diagnostics
2023/2/16
Sadakatsu Ikeda
H-Index: 19
Identification of risk factors for gastrointestinal irAEs associated with immune checkpoint inhibitors.
2023/2/1
Shingo Sato
H-Index: 4
Sadakatsu Ikeda
H-Index: 19
Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer
BMC cancer
2023/1/23
Sadakatsu Ikeda
H-Index: 19
First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors
Cancer
2022/8/1
Fuyuki Miya
H-Index: 15
Sadakatsu Ikeda
H-Index: 19
Comprehensive genomic profiling reveals clinical associations in response to immune therapy in head and neck cancer
Cancers
2022/7/18
MO28-5 Clinical utility of comprehensive genomic profiling for patients with cancer of unknown primary site
Annals of Oncology
2022/7/1
P68-5 Prospective trial of comprehensive genomic profiling for patients with chemotherapy-naïve cancer (FIRST-Dx trial)
Annals of Oncology
2022/7/1
Sadakatsu Ikeda
H-Index: 19
Ovarian Carcinosarcoma Associated with Cowden Syndrome-A Case Report
Gan to Kagaku ryoho. Cancer & Chemotherapy
2022/7/1
Sadakatsu Ikeda
H-Index: 19
Masayuki Yoshida
H-Index: 19
Tumor immune characterization identifies age-stratified biomarkers for nivolumab in patients with head and neck squamous cell carcinoma: A nationwide collaborative study in Japan
Cancer Research
2022/6/15
Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors.
2022/6/1
Sadakatsu Ikeda
H-Index: 19
Clinical trial matching apparatus
2022/5/19
Clinical utility of comprehensive genomic profiling in Japan: Result of PROFILE-F study
Neuro-Oncology Advances
2021/1/1
